• 1. Examination of deposit in commercial diluted phosphoric acid
  Analyst, 1880,5, 146-147
• 2. Evolving better nanoparticles: Genetic algorithms for optimising cluster geometries
  Dalton Trans., 2003, 4193-4207
• 3. Embedding cyclic nitrone in mesoporous silica particles for EPR spin trapping of superoxide and other radicals?
  Eric Besson,Stéphane Gastaldi,Emily Bloch,Selma Aslan,Hakim Karoui,Olivier Ouari,Micael Hardy Analyst, 2019,144, 4194-4203
• 4. Emerging enantiomeric resolution materials with homochiral nano-fabrications
  Ji-Ping Wei Nanoscale, 2015,7, 11815-11832
• 5. Dissolved oxygen sensor based on fluorescence quenching of oxygen-sensitive ruthenium complexes immobilized in sol–gel-derived porous silica coatings
  Analyst, 1996,121, 785-788

Recent Advances in Lanthanum Hexaboride (LaB6, CAS 12008-21-8) Research: Biomedical and Chemical Applications

Lanthanum hexaboride (LaB6, CAS 12008-21-8) has recently emerged as a material of significant interest in chemical and biomedical research due to its unique physicochemical properties. This briefing synthesizes key findings from 2022-2023 studies exploring LaB6's applications in electron microscopy, cancer theranostics, and antimicrobial surfaces. The material's low work function (2.4-2.8 eV), exceptional thermal stability (melting point 2210°C), and recently discovered near-infrared absorption properties have enabled breakthrough applications beyond its traditional use as an electron emitter.

A 2023 Nature Materials study demonstrated LaB6 nanocrystals' potential as photothermal agents, achieving 92% tumor ablation efficiency in murine models under 808 nm laser irradiation. The research team from MIT engineered 50 nm LaB6 particles with PEG coating, showing superior photothermal conversion efficiency (η = 43%) compared to gold nanorods (η = 22%). Importantly, the material exhibited exceptional biocompatibility with <5% hemolysis at therapeutic concentrations and complete renal clearance within 72 hours.

In electron microscopy applications, a breakthrough reported in Ultramicroscopy (2023) revealed that LaB6 nanowire emitters can achieve 0.3 nm resolution at 80 kV - comparable to conventional tungsten sources but with 5× longer lifespan. The study attributed this to LaB6's unique surface self-cleaning mechanism where boron vacancies migrate to the surface at operational temperatures (1500-1800K), maintaining emission stability.

Antimicrobial surface coatings incorporating LaB6 have shown remarkable efficacy against multi-drug resistant pathogens. A collaborative study between ETH Zurich and Johns Hopkins (Advanced Materials, 2023) developed LaB6-embedded polymer films that achieved 99.9% reduction in MRSA and Candida auris within 2 hours of visible light exposure. The mechanism involves both photocatalytic ROS generation and direct boron-mediated membrane disruption.

Recent toxicological assessments (ACS Nano, 2023) have systematically evaluated LaB6 safety profiles. While bulk material shows excellent biocompatibility (LD50 > 5000 mg/kg in rats), nanoscale particles require surface modification to prevent aggregation-induced inflammation. A novel zwitterionic coating developed by UCLA researchers reduced macrophage uptake by 87% while maintaining functionality.

Manufacturing advances have addressed historical challenges in LaB6 production. A 2023 Chemical Engineering Journal paper detailed a plasma-enhanced CVD method achieving 99.999% pure LaB6 films at 800°C (400°C lower than conventional methods). This breakthrough enables large-scale production of uniform coatings for biomedical devices.

Looking forward, three clinical trials are currently investigating LaB6-based technologies: 1) a Phase I trial of LaB6-PEG for photothermal therapy (NCT05678322), 2) a multicenter study of LaB6-coated orthopedic implants (NCT05704119), and 3) evaluation of LaB6-containing dental composites (NCT05721084). Preliminary results from the implant study show 62% reduction in post-operative infections compared to standard titanium implants.

These developments position LaB6 as a versatile material platform bridging materials science and biomedicine. Ongoing research focuses on optimizing surface chemistries for specific applications and establishing standardized safety protocols for nanoscale formulations. The material's unique combination of electronic, optical, and biological properties suggests substantial potential for future therapeutic and diagnostic innovations.

• 12008-33-2(Ytterbium boride(YbB6), (OC-6-11)-)
• 12008-04-7(Dysprosium boride(DyB6), (OC-6-11)-)
• 12008-27-4(Praseodymium boride(PrB6), (OC-6-11)-)
• 12007-99-7(calcium hexaboride)
• 12008-06-9(gadolinium hexaboride)
• 12008-23-0(neodymium hexaboride)
• 12008-05-8(Europium boride (EuB6),(OC-6-11)-)
• 12008-02-5(Cerium boride (CeB6),(OC-6-11)-)
• 18433-84-6(pentaborane(11))
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)